Eli Lilly and Company has emerged as in the development and tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve glycemic control and reduce cardiovascular risks. The sophisticated synthesis of tirze